A Note From The CEO
by Anthony Sampietro, Co-Founder & Chief Executive Officer
2019 was an extraordinary year for Ocular Science® and our affiliates OSRXTM and Regenerative ScienceTM. We exceeded revenue and commercial goals across the board, thanks largely to an unprecedented surge of growth from OSRX, our 503A ophthalmic compounding pharmacy, which formulates 14 combinations of medications for post-op cataract and LASIK treatment, glaucoma management, myopia control, and soon, presbyopia. In short, we were profitable in Q3 and Q4, emerging with a 90% compound annual growth rate – an amazing feat for a company as young as ours.
The past year’s success was driven by a multitude of factors, namely the solidification of our leadership team and several key additions to the Ocular Science Board of Directors and Medical Advisory Board. Adding these “A players” has only amplified the astute, one-of-a-kind guidance and industry insights we leverage on a daily basis.
However, the buck ultimately starts and stops with the quality of our formulations and our organizational integrity – two core values we refuse to compromise. We’re not shy about the fact we aren’t Big Pharma, and our new view of medicine continues to win acceptance from prescribers across the country.
We do, in fact, take inordinate pride in going the extra mile to help physicians and their patients. We are currently beginning to roll out our OSRX Prescriber Portal, which allows physicians to submit prescriptions for compounded formulations directly through our website. Physicians and patients can also track the status and delivery of prescriptions via the secure portal. Email us at firstname.lastname@example.org to begin utilizing the portal.
I’m energized every day to have the opportunity to offer practical solutions coupled with paradigm-shifting innovations to transform how physicians and patients view traditional medicine. These are exciting times for Ocular Science. Our dream of reshaping the American ophthalmology marketplace is becoming a reality.
It’s true, “We See Things Differently.”